Please assess the completion status of the following clinical trial:

Trial Title: Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of cystic fibrosis patients with Pseudomonas aeruginosa infection.~* Male and female subjects between 6 and 21 years of age at the time of screening.~* FEV1 at screening must be between 25% and 80% of normal predicted values.~Exclusion Criteria:~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).